Visceral leishmaniasis and HIV coinfection: current perspectives

José Angelo Lauletta Lindoso,1–3 Carlos Henrique Valente Moreira,1,4 Mirella Alves Cunha,5 Igor Thiago Queiroz6,7 1Instituto de Infectologia Emilio Ribas, São Paulo, Brazil; 2Nucleo de Medicina Tropical, Universidade de Brasília, Brasília, Brazil...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lindoso JAL, Moreira CHV, Cunha MA, Queiroz IT
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Visceral leishmaniasis HIV infection AIDS Diagnosis Therapeutic Response Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/041948f726a34a019efaa87a834998a5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:041948f726a34a019efaa87a834998a5
record_format	dspace
spelling	oai:doaj.org-article:041948f726a34a019efaa87a834998a52021-12-02T07:05:51ZVisceral leishmaniasis and HIV coinfection: current perspectives1179-1373https://doaj.org/article/041948f726a34a019efaa87a834998a52018-10-01T00:00:00Zhttps://www.dovepress.com/visceral-leishmaniasis-and-hiv-coinfection-current-perspectives-peer-reviewed-article-HIVhttps://doaj.org/toc/1179-1373José Angelo Lauletta Lindoso,1–3 Carlos Henrique Valente Moreira,1,4 Mirella Alves Cunha,5 Igor Thiago Queiroz6,7 1Instituto de Infectologia Emilio Ribas, São Paulo, Brazil; 2Nucleo de Medicina Tropical, Universidade de Brasília, Brasília, Brazil; 3Laboratorio de Soroepidemiologia, Institutode Medicina Tropical, Universidade de São Paulo, São Paulo, Brazil; 4Laboratorio de Parasitologia, Instituto de Medicina Tropical, Universidade de São Paulo, São Paulo, Brazil; 5Departamento de Infectologia, Universidade Federal do Rio Grande do Norte, Natal, Brazil; 6Universidade Potiguar (UnP), Laureate International Universities, Natal, Brazil; 7Hospital Giselda Trigueiro (SESAP/RN), Natal, Brazil Abstract: Visceral leishmaniasis (VL) is caused by Leishmania donovani and Leishmania infantum. The burden of VL is concentrated in tropical and subtropical areas; however, HIV infection has spread VL over a hyperendemic area. Several outcomes are observed as a result of VL–HIV coinfection. Impacts are observed in immunopathogenesis, clinical manifestation, diagnosis, and therapeutic response. Concerning clinical manifestation, typical and unusual manifestation has been observed during active VL in HIV-infected patient, as well as alteration in immunoresponse, inducing greater immunosuppression by low CD4 T-lymphocyte count or even by induction of immunoactivation, with cell senescence. Serological diagnosis of VL in the HIV-infected is poor, due to low humoral response, characterized by antibody production, so parasitological methods are more recommended. Another important and even more challenging point is the definition of the best therapeutic regimen for VL in HIV-coinfected patients, because in this population there is greater failure and consequently higher mortality. The challenge of better understanding immunopathogenesis in order to obtain more effective therapies is one of the crucial points to be developed. The combination of drugs and the use of secondary prophylaxis associated with highly active antiretroviral therapy may be the best tool for treatment of HIV coinfection. Some derivatives from natural sources have action against Leishmania; however, studies have been limited to in vitro evaluation, without clinical trials. Keywords: visceral leishmaniasis, HIV infection, AIDS, diagnosis, therapeutic responseLindoso JALMoreira CHVCunha MAQueiroz ITDove Medical PressarticleVisceral leishmaniasisHIV infectionAIDSDiagnosisTherapeutic ResponseImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol Volume 10, Pp 193-201 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Visceral leishmaniasis HIV infection AIDS Diagnosis Therapeutic Response Immunologic diseases. Allergy RC581-607
spellingShingle	Visceral leishmaniasis HIV infection AIDS Diagnosis Therapeutic Response Immunologic diseases. Allergy RC581-607 Lindoso JAL Moreira CHV Cunha MA Queiroz IT Visceral leishmaniasis and HIV coinfection: current perspectives
description	José Angelo Lauletta Lindoso,1–3 Carlos Henrique Valente Moreira,1,4 Mirella Alves Cunha,5 Igor Thiago Queiroz6,7 1Instituto de Infectologia Emilio Ribas, São Paulo, Brazil; 2Nucleo de Medicina Tropical, Universidade de Brasília, Brasília, Brazil; 3Laboratorio de Soroepidemiologia, Institutode Medicina Tropical, Universidade de São Paulo, São Paulo, Brazil; 4Laboratorio de Parasitologia, Instituto de Medicina Tropical, Universidade de São Paulo, São Paulo, Brazil; 5Departamento de Infectologia, Universidade Federal do Rio Grande do Norte, Natal, Brazil; 6Universidade Potiguar (UnP), Laureate International Universities, Natal, Brazil; 7Hospital Giselda Trigueiro (SESAP/RN), Natal, Brazil Abstract: Visceral leishmaniasis (VL) is caused by Leishmania donovani and Leishmania infantum. The burden of VL is concentrated in tropical and subtropical areas; however, HIV infection has spread VL over a hyperendemic area. Several outcomes are observed as a result of VL–HIV coinfection. Impacts are observed in immunopathogenesis, clinical manifestation, diagnosis, and therapeutic response. Concerning clinical manifestation, typical and unusual manifestation has been observed during active VL in HIV-infected patient, as well as alteration in immunoresponse, inducing greater immunosuppression by low CD4 T-lymphocyte count or even by induction of immunoactivation, with cell senescence. Serological diagnosis of VL in the HIV-infected is poor, due to low humoral response, characterized by antibody production, so parasitological methods are more recommended. Another important and even more challenging point is the definition of the best therapeutic regimen for VL in HIV-coinfected patients, because in this population there is greater failure and consequently higher mortality. The challenge of better understanding immunopathogenesis in order to obtain more effective therapies is one of the crucial points to be developed. The combination of drugs and the use of secondary prophylaxis associated with highly active antiretroviral therapy may be the best tool for treatment of HIV coinfection. Some derivatives from natural sources have action against Leishmania; however, studies have been limited to in vitro evaluation, without clinical trials. Keywords: visceral leishmaniasis, HIV infection, AIDS, diagnosis, therapeutic response
format	article
author	Lindoso JAL Moreira CHV Cunha MA Queiroz IT
author_facet	Lindoso JAL Moreira CHV Cunha MA Queiroz IT
author_sort	Lindoso JAL
title	Visceral leishmaniasis and HIV coinfection: current perspectives
title_short	Visceral leishmaniasis and HIV coinfection: current perspectives
title_full	Visceral leishmaniasis and HIV coinfection: current perspectives
title_fullStr	Visceral leishmaniasis and HIV coinfection: current perspectives
title_full_unstemmed	Visceral leishmaniasis and HIV coinfection: current perspectives
title_sort	visceral leishmaniasis and hiv coinfection: current perspectives
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/041948f726a34a019efaa87a834998a5
work_keys_str_mv	AT lindosojal visceralleishmaniasisandhivcoinfectioncurrentperspectives AT moreirachv visceralleishmaniasisandhivcoinfectioncurrentperspectives AT cunhama visceralleishmaniasisandhivcoinfectioncurrentperspectives AT queirozit visceralleishmaniasisandhivcoinfectioncurrentperspectives
_version_	1718399555798564864

Visceral leishmaniasis and HIV coinfection: current perspectives

Ejemplares similares